Connect your AI

Regenxbio RGNX Change in Other Assets

Change in Other Assets at other companies

Sarepta Therapeutics, Inc.SRPT

$14.55M-3.5%

BioMarin PharmaceuticalsBMRN

-$1.48M-191%

EyePoint, Inc. EYPT

$3.36M+7,534%

4D Molecular TherapeuticsFDMT

$670K-75.9%

Solid Biosciences Inc.SLDB

-$954K+52.8%

Immix Biopharma, Inc.IMMX

$866.6K+174%

Other financials

Income statement

Revenue$6.4M-92.8%

Gross profit$14.9M+35.7%

Operating income-$83.4M-787%

Net income-$90.1M-1,580%

EPS (diluted)-$1.72-1,533%

Balance sheet

Cash & equivalents$15.2M-88.3%

Total debt$71.1M-11.0%

Total equity$21.1M-92.3%

Total assets$341.9M-30.4%

Cash flow

Operating cash flow-$76.2M-327%

CapEx$1.2M+20.6%

Free cash flow-$77.4M-337%

Valuation

Market cap$529.38M+24.6%

Enterprise value$585.22M+56.3%

P/S6×+3.3×

Profitability

Gross margin59.7%+1.0pp

Operating margin-292.3%-613pp

Net margin-330.2%-588pp

FCF margin-269.2%-364pp

Returns & leverage

Return on equity-196.4%-288pp

Debt / equity3.4×+3.1×

Current ratio2.6×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentAssets.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Regenxbio's change in other assets?: Regenxbio (RGNX) reported change in other assets of $900K in Q1 2026.
How has Regenxbio's change in other assets changed year-over-year?: Regenxbio's change in other assets increased by 188.8% year-over-year, from -$1.01M to $900K.
What does change in other assets mean?: Change in miscellaneous assets affecting operating cash flow.